MiRNA
|
Tissue
|
Grade
|
n
|
Mean (SD)
|
Contrasts
|
p*
|
---|
miR-17-5p
|
Benign
|
–
|
36
|
6.67 (0.68)
| | |
Cancer
|
All
|
102
|
6.32 (0.66)
|
Cancer vs benign
|
0.014
|
Cancer
|
1
|
32
|
6.10 (0.45)
|
Grade 1 vs 2 and 3
|
0.0040
|
Cancer
|
2
|
41
|
6.16 (0.48)
|
Grade 1 and 2 vs 3
|
2.45E−5
|
Cancer
|
3
|
27
|
6.82 (0.85)
|
Grade 1 vs 3
|
6.84E−5
|
miR-20a-5p
|
Benign
|
–
|
36
|
7.34 (0.74)
| | |
Cancer
|
All
|
102
|
6.69 (0.60)
|
Cancer vs benign
|
1.23E−6
|
Cancer
|
1
|
32
|
6.54 (0.38)
|
Grade 1 vs 2 and 3
|
0.014
|
Cancer
|
2
|
41
|
6.52 (0.39)
|
Grade 1 and 2 vs 3
|
2.45E−5
|
Cancer
|
3
|
27
|
7.14 (0.82)
|
Grade 1 vs 3
|
8.50E−5
|
miR-92a-3p
|
Benign
|
–
|
36
|
7.79 (0.62)
| | |
Cancer
|
All
|
102
|
7.23 (0.52)
|
Cancer vs benign
|
1.23E−6
|
Cancer
|
1
|
32
|
7.19 (0.47)
|
Grade 1 vs 2 and 3
|
0.27
|
Cancer
|
2
|
41
|
7.06 (0.42)
|
Grade 1 and 2 vs 3
|
0.00037
|
Cancer
|
3
|
27
|
7.55 (0.59)
|
Grade 1 vs 3
|
0.0068
|
miR-106b-5p
|
Benign
|
–
|
36
|
6.68 (0.59)
| | |
Cancer
|
All
|
102
|
6.56 (0.51)
|
Cancer vs benign
|
0.24
|
Cancer
|
1
|
32
|
6.36 (0.38)
|
Grade 1 vs 2 and 3
|
0.0019
|
Cancer
|
2
|
41
|
6.49 (0.44)
|
Grade 1 and 2 vs 3
|
6.84E−5
|
Cancer
|
3
|
27
|
6.91 (0.61)
|
Grade 1 vs 3
|
6.84E−5
|
miR-93-5p
|
Benign
|
–
|
36
|
6.81 (0.41)
| | |
Cancer
|
All
|
102
|
7.00 (0.56)
|
Cancer vs benign
|
0.095
|
Cancer
|
1
|
32
|
6.80 (0.39)
|
Grade 1 vs 2 and 3
|
0.0032
|
Cancer
|
2
|
41
|
6.92 (0.47)
|
Grade 1 and 2 vs 3
|
6.84E−5
|
Cancer
|
3
|
27
|
7.39 (0.69)
|
Grade 1 vs 3
|
8.50E−5
|
miR-25-3p
|
Benign
|
–
|
36
|
6.63 (0.33)
| | |
Cancer
|
All
|
102
|
6.54 (0.33)
|
Cancer vs benign
|
0.19
|
Cancer
|
1
|
32
|
6.44 (0.23)
|
Grade 1 vs 2 and 3
|
0.013
|
Cancer
|
2
|
41
|
6.48 (0.28)
|
Grade 1 and 2 vs 3
|
0.00016
|
Cancer
|
3
|
27
|
6.75 (0.41)
|
Grade 1 vs 3
|
0.00043
|
- Expression levels are given as the mean (standard deviation) of log2 transformed intensity values (Hy3) by microarray analyses
- * False discovery rate (FDR) adjusted p-value. E indicates exponential number